The Trump Administration’s first significant legal filing in mifepristone litigation defends the US Food and Drug Administration’s 2023 decision on the abortion medication’s Risk Evaluation and Mitigation Strategy.
Mifepristone Filing Supports 2023 US FDA Actions, But Experts Caution Against Overanalyzing
Filing in the Whole Women’s Health mifepristone case defends the FDA’s 2023 decision on the abortion pill safety program, but experts warn it does not necessarily signal the Trump Administration position in other mifepristone cases attempting to restrict medication abortion access.
